| pubmed-article:6257790 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6257790 | lifeskim:mentions | umls-concept:C0221920 | lld:lifeskim |
| pubmed-article:6257790 | lifeskim:mentions | umls-concept:C0033860 | lld:lifeskim |
| pubmed-article:6257790 | lifeskim:mentions | umls-concept:C0018338 | lld:lifeskim |
| pubmed-article:6257790 | lifeskim:mentions | umls-concept:C0221198 | lld:lifeskim |
| pubmed-article:6257790 | lifeskim:mentions | umls-concept:C0205217 | lld:lifeskim |
| pubmed-article:6257790 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:6257790 | pubmed:dateCreated | 1981-4-13 | lld:pubmed |
| pubmed-article:6257790 | pubmed:abstractText | Cyclic GMP levels in epidermis of normal subjects and of psoriatic patients were measured with a highly sensitive radioimmunoassay method. Technical improvements for the assay are 2-fold: (1) skin samples were frozen in vivo before biopsy and local injection of any anesthetic was avoided to overcome ischemia effect which could lower cyclic GMP artificially; (2) epidermis was microdissected to avoid contamination of dermis and keratin layers. The results show that on a per mg tissue dry weight basis the cyclic GMP levels are about 200 fmol in the involved lesional epidermis and 70 fmol in the uninvolved or normal epidermis. Similarly increases in the cyclic GMP levels in the lesional epidermis are observed when the data are expressed either on a DNA or protein basis. The cyclic GMP level in normal epidermis from nonpsoriatic subjects is the same as that in the uninvolved epidermis of psoriasis patients. | lld:pubmed |
| pubmed-article:6257790 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6257790 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6257790 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6257790 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6257790 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6257790 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6257790 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:6257790 | pubmed:issn | 0022-202X | lld:pubmed |
| pubmed-article:6257790 | pubmed:author | pubmed-author:AdachiKK | lld:pubmed |
| pubmed-article:6257790 | pubmed:author | pubmed-author:AoyagiTT | lld:pubmed |
| pubmed-article:6257790 | pubmed:author | pubmed-author:HalprinK MKM | lld:pubmed |
| pubmed-article:6257790 | pubmed:author | pubmed-author:LevineVV | lld:pubmed |
| pubmed-article:6257790 | pubmed:author | pubmed-author:NemotoOO | lld:pubmed |
| pubmed-article:6257790 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6257790 | pubmed:volume | 76 | lld:pubmed |
| pubmed-article:6257790 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6257790 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6257790 | pubmed:pagination | 19-20 | lld:pubmed |
| pubmed-article:6257790 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:6257790 | pubmed:meshHeading | pubmed-meshheading:6257790-... | lld:pubmed |
| pubmed-article:6257790 | pubmed:meshHeading | pubmed-meshheading:6257790-... | lld:pubmed |
| pubmed-article:6257790 | pubmed:meshHeading | pubmed-meshheading:6257790-... | lld:pubmed |
| pubmed-article:6257790 | pubmed:meshHeading | pubmed-meshheading:6257790-... | lld:pubmed |
| pubmed-article:6257790 | pubmed:year | 1981 | lld:pubmed |
| pubmed-article:6257790 | pubmed:articleTitle | Epidermal cyclic GMP is increased in psoriasis lesions. | lld:pubmed |
| pubmed-article:6257790 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6257790 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:6257790 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6257790 | lld:pubmed |
